14.03.2014 • News

Codexis sells Hungarian operations to Intrexon Corporation

Codexis today announced the sale of its Hungarian subsidiary to Intrexon Corporation. The transaction closed on March 13, with a purchase price of US$ 1.5 million. No proprietary Codexis materials or intellectual property were included in the transaction. "We are very pleased with this transaction," said John Nicols, President and CEO of Codexis. "We were able to transfer our dedicated and talented employees in Hungary to Intrexon and to monetize one of our assets as part of the wind down of our biofuels business."

Company

Codexis

200 Penobscot Drive
Redwood City

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.